Choi, Sehee
Cha, Pu-Hyeon
Kim, Hyun-Yi
Choi, Kang-Yell
Funding for this research was provided by:
National Research Foundation of Korea (2015R1A2A1A05001873, 2019R1A2C3002751, 2016R1A5A1004694)
Article History
Received: 11 April 2019
Revised: 7 May 2019
Accepted: 15 May 2019
First Online: 12 September 2019
Conflict of interest
: K.-Y.C. is the CEO of CK Biotechnology Inc., headquartered in Seoul, Korea, which has a license to develop and use the compounds disclosed in the publication. The remaining authors declare that they have no conflict of interest.